About swedish orphan biovitrum ab - BIOVF
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life-threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden.
BIOVF At a Glance
Swedish Orphan Biovitrum AB
Tomtebodavägen 23A
Solna, Stockholm 112 76
| Phone | 46-8-697-20-00 | Revenue | 2.08B | |
| Industry | Pharmaceuticals: Major | Net Income | 226.92M | |
| Sector | Health Technology | 2023 Sales Growth | 12.242% | |
| Fiscal Year-end | 12 / 2024 | Employees | 1,772 | |
| View SEC Filings |
BIOVF Valuation
| P/E Current | 28.189 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 37.671 |
| Price to Sales Ratio | 4.144 |
| Price to Book Ratio | 2.679 |
| Price to Cash Flow Ratio | 20.51 |
| Enterprise Value to EBITDA | 14.352 |
| Enterprise Value to Sales | 5.076 |
| Total Debt to Enterprise Value | 0.192 |
BIOVF Efficiency
| Revenue/Employee | 1,176,092.051 |
| Income Per Employee | 128,060.285 |
| Receivables Turnover | 2.974 |
| Total Asset Turnover | 0.337 |
BIOVF Liquidity
| Current Ratio | 0.664 |
| Quick Ratio | 0.461 |
| Cash Ratio | 0.047 |
BIOVF Profitability
| Gross Margin | 63.519 |
| Operating Margin | 21.045 |
| Pretax Margin | 13.352 |
| Net Margin | 10.889 |
| Return on Assets | 3.665 |
| Return on Equity | 7.684 |
| Return on Total Capital | 4.208 |
| Return on Invested Capital | 6.171 |
BIOVF Capital Structure
| Total Debt to Total Equity | 60.487 |
| Total Debt to Total Capital | 37.69 |
| Total Debt to Total Assets | 27.672 |
| Long-Term Debt to Equity | 34.027 |
| Long-Term Debt to Total Capital | 21.203 |